Equities

Acme United Corp

Acme United Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)41.51
  • Today's Change-0.02 / -0.05%
  • Shares traded35.60k
  • 1 Year change+31.82%
  • Beta0.6569
Data delayed at least 15 minutes, as of Nov 09 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Acme United Corp have a median target of 53.25, with a high estimate of 58.00 and a low estimate of 48.50. The median estimate represents a 28.28% increase from the last price of 41.51.
High39.7%58.00
Med28.3%53.25
Low16.8%48.50

Dividends

Dividend information is not available for Acme United Corp.
Div growth (TTM)3.64%
More ▼

Earnings history & estimates in USD

On Oct 18, 2024, Acme United Corp reported 3rd quarter 2024 earnings of 0.540 per share.
The next earnings announcement is expected on Feb 27, 2025.
Average growth rate+23.87%
Acme United Corp reported annual 2023 earnings of 2.23 per share on Mar 01, 2024.
Average growth rate+39.87%
More ▼

Revenue history & estimates in USD

Acme United Corporation had 3rd quarter 2024 revenues of 48.17m. This missed the 53.41m estimate of the one analyst following the company. This was 5.08% above the prior year's 3rd quarter results.
Average growth rate+0.16%
Acme United Corporation had revenues for the full year 2023 of 191.50m. This was 1.27% below the prior year's results.
Average growth rate+7.85%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.